A novel preemptive approach to plerixafor use in mobilization failure

Basit Öğe Kaydı
dc.contributor.authorKaya, Ahmet
dc.contributor.authorErkurt, Mehmet Ali
dc.contributor.authorKuku, Irfan
dc.contributor.authorKaya, Emin
dc.contributor.authorBerber, Ilhami
dc.contributor.authorSarici, Ahmet
dc.contributor.authorArslan, Suleyman
dc.date.accessioned2026-04-04T13:30:43Z
dc.date.available2026-04-04T13:30:43Z
dc.date.issued2026
dc.departmentİnönü Üniversitesi
dc.description.abstractObjective: Plerixafor is a highly effective mobilization agent in cases of mobilization failure. We aimed to clarify whether early administration of plerixafor after stem cell collection failure results in outcomes similar to those achieved with later administration. Patients and Methods: Sixty-six autologous stem cell transplantation patients who received plerixafor for mobilization failure were included in the study. Patients were divided into two groups; patients receiving early plerixafor [receiving granulocyte-colony stimulation factor (G-CSF) for 2 or 3 days] and standard plerixafor (receiving G-CSF for 4 days). Both groups were evaluated in terms of neutrophil and platelet engraftment time, CD34 stem cell levels, and side effects. Results: There was no significant difference between the two groups-early plerixafor and standard plerixafor-in terms of neutrophil and platelet engraftment times, CD34+ stem cell counts, and adverse effects (CD34/p = 0.201; neutrophil/p = 0.415; platelet/p = 0.077; adverse effects/p = 0.439). No differences were observed between the groups regarding age, gender, transplant type, plerixafor preparation, adverse effects, or transplant conditioning regimen. Additionally, there was no difference in transplant conditioning regimen between surviving and deceased patients. Conclusion: While the use of G-CSF alone is routine in stem cell mobilization, the addition of plerixafor is preferred in cases of mobilization failure. Although chemotherapy-based mobilization is included in mobilization schemes, its use is very limited today. It was concluded that plerixafor is a highly effective agent for mobilization, can be used safely in cases of failure in stem cell collection, and that its early use in patients with insufficient reserve may be more cost-effective.
dc.identifier.doi10.5472/marumj.1872989
dc.identifier.endpage31
dc.identifier.issn1309-9469
dc.identifier.issue1
dc.identifier.scopus2-s2.0-105030184197
dc.identifier.scopusqualityN/A
dc.identifier.startpage24
dc.identifier.urihttps://doi.org/10.5472/marumj.1872989
dc.identifier.urihttps://hdl.handle.net/11616/108329
dc.identifier.volume39
dc.identifier.wosWOS:001681465500004
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.language.isoen
dc.publisherMarmara Univ, Fac Medicine
dc.relation.ispartofMarmara Medical Journal
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_WOS_20250329
dc.subjectAutologous stem cell transplantation
dc.subjectMobilization
dc.subjectPlerixafor
dc.titleA novel preemptive approach to plerixafor use in mobilization failure
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu